We are live on ! Find out more
KCA

KVP Capital Advisors Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+33.24%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$30.6M
Cap. Flow
+$26M
Cap. Flow %
19.42%
Top 10 Hldgs %
61.06%
Holding
36
New
9
Increased
1
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
STRO icon
Sutro Biopharma
STRO
+$4.09M
2
ERAS icon
Erasca
ERAS
+$4.02M
3
VRDN icon
Viridian Therapeutics
VRDN
+$3.71M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.2M
5
CMPX icon
Compass Therapeutics
CMPX
+$2.89M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$2.98M
2
FULC icon
Fulcrum Therapeutics
FULC
+$566K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
26
DELISTED
Soleno Therapeutics
SLNO
$2M 1.49%
59,700
– –
NKTR icon
27
Nektar Therapeutics
NKTR
$2.48B
$1.94M 1.45%
26,900
– –
CABA icon
28
Cabaletta Bio
CABA
$529M
$1.36M 1.02%
505,431
– –
ACHV icon
29
Achieve Life Sciences
ACHV
$834M
$1.36M 1.02%
462,355
– –
VERA icon
30
Vera Therapeutics
VERA
$2.46B
$1.32M 0.98%
32,700
– –
CELC icon
31
Celcuity
CELC
$4.33B
$457K 0.34%
4,000
– –
YARW
32
Yarrow Bioscience
YARW
$98.8M
$299K 0.22%
10,011
– –
FULC icon
33
CALL
Fulcrum Therapeutics
FULC
$294M
– –
-110,900
Closed -$1.25M
FULC icon
34
Fulcrum Therapeutics
FULC
$294M
– –
-50,000
Closed -$566K
JAZZ icon
35
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-31,000
Closed -$5.27M
JAZZ icon
36
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-17,500
Closed -$2.98M
1
2

Similar funds

RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
SCM
Sidoxia Capital Management Newport Beach, California $136M AUM
VSCP
Vesey Street Capital Partners New York $136M AUM 6.83% 1-Year Est. Return

KVP Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, KVP Capital Advisors held 36 positions worth $134M, up 30% from $103M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

KVP Capital Advisors deployed $26M of net new capital in Q1 2026, opening 9 new positions and adding to 1 existing holding. Its largest new stake was Sutro Biopharma: 226,575 shares worth $5.64M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

On the sell side, the most notable exit was Jazz Pharmaceuticals, an estimated $2.98M sold.

  • KVP Capital Advisors's largest Q1 2026 buy was Sutro Biopharma: 226,575 shares worth $5.64M.
  • KVP Capital Advisors added most to Revolution Medicines in Q1 2026, an estimated $1.28M increase.
  • KVP Capital Advisors fully exited Jazz Pharmaceuticals in Q1 2026, selling an estimated $2.98M.
  • KVP Capital Advisors's ten largest holdings make up 61% of its $134M portfolio in Q1 2026.
  • KVP Capital Advisors opened 9 new positions and closed 4 in Q1 2026.
  • KVP Capital Advisors's portfolio value rose 30% quarter-over-quarter to $134M.

Based on KVP Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.